Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.

Starting at $599 per month, some people were able to get prescribed to Wegovy and a Hims & Hers membership. That was much cheaper than the previous cost of paying $1,999 per month for Wegovy on ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

SAN FRANCISCO, CA / ACCESS Newswire / July 21, 2025 / On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE:HIMS)and certain of the company's executives.

Hims shares fell $22.24, or over 34%, after Novo’s announcement, declining from $64.22 per share on June 20 to close at $41.98 per share on June 23. The stock closed on Monday at $52.03 a share.

All dose sizes of Wegovy will be available through Hims & Hers starting at $599 per month. Hims & Hers says this also includes 24/7 care, nutritional guidance and ongoing clinical support.

Business Economy Health Technology Hims & Hers’ ugly split with Wegovy maker weighs on the firm’s future July 7, 2025 at 6:00 am Updated July 7, 2025 at 6:00 am By Queenie Wong ...

SAN FRANCISCO, CA / ACCESS Newswire / July 16, 2025 / On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE:HIMS)and certain of the company's executives.